tbuckley/cabot-search huggingface dataset:
Efficacy of <scp>BI</scp> 655064 in improving renal outcome in patients with lupus nephritis
Authors: Mi Zhou, Ru‐yang Jing, Li‐xue Yin
Journal: Arthritis & Rheumatology (2025)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Hydroxychloroquine dose after hospitalization for <scp>SLE</scp>: comment on the article by Nestor and colleagues
Authors: Berçemhan Sulu, Koray Taşcılar
Journal: Arthritis & Rheumatology (2025)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Unveiling the Pathways to Cardiovascular Disease in Systemic Lupus Erythematosus
Authors: Yusuf Ziya Sener, Seher Sener
Journal: Arthritis & Rheumatology (2025)

Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
The Burden of Steatotic Liver Disease before and during the COVID Pandemic Correspondence to editorial on “Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD in the COVID-19 pandemic (CMH-2025-0019)”
Authors: Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed
Journal: Clinical and Molecular Hepatology (2025)

The Burden of Steatotic Liver Disease before and during the COVID Pandemic Correspondence to editorial on "Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD in the COVID-19 pandemic (CMH-2025-0019)"
Cardiomyocyte SORBS2 expression increases in heart failure and regulates integrin interactions and extracellular matrix composition
Authors: Louk T Timmer, Elvira den Hertog, Danielle Versteeg, Harm Post, Job A J Verdonschot, Jantine Monshouwer-Kloots, Eirini Kyriakopoulou, Ilaria Perini, Tim Koopmans, Petra van der Kraak, Lorena Zentilin, Stephane R B Heymans, Aryan Vink, Mauro Giacca, Albert J R Heck, Eva van Rooij
Journal: Cardiovascular Research (2025)

Abstract Aims In this study, we aimed to uncover genes associated with stressed cardiomyocytes by combining single-cell transcriptomic datasets from failing cardiac tissue from both humans and mice Methods and results Our bioinformatic analysis identified SORBS2 as conserved NPPA correlated gene. Using mouse models and cardiac tissue from human heart failure patients, we demonstrated that SORBS2 expression is consistently increased during pathological remodeling, correlates to disease severity and is regulated by GATA4. By affinity-purification mass-spectrometry, we showed SORBS2 to interact with the integrin-cytoskeleton connections. Cardiomyocyte-specific genetic loss of Sorbs2 in adult mice changed integrin interactions, indicated by the increased expression of several integrins and altered extracellular matrix components connecting to these integrins, leading to an exacerbated fibrotic response during pathological remodeling. Conclusions Sorbs2 is a cardiomyocyte-enriched gene that is increased during progression to heart failure in a GATA4-dependent manner and correlates to phenotypical hallmarks of cardiac failure. Our data indicate SORBS2 to function as a crucial regulator of integrin interactions and cardiac fibrosis.
NSUN2-mediated HCV RNA m5C Methylation Facilitates Viral RNA Stability and Replication
Authors: Zhu-Li Li, Yan Xie, Yafen Wang, Jing Wang, Xiang Zhou, Xiao-Lian Zhang
Journal: Genomics Proteomics & Bioinformatics (2025)

RNA modifications have emerged as new efficient targets against viruses. However, little is known about 5-methylcytosine (m5C) modification in the genomes of Flaviviruses. Herein, we demonstrate that hepatitis C virus (HCV), dengue virus, and Zika virus contain high levels of viral RNA m5C modification. We find that m5C modification in HCV RNA genome is located at C7525 site in the viral NS5A gene. HCV infection increases host m5C machinery NSUN2 expression via transcription factor E2F1. Deficiency of NSUN2 decreases HCV RNA m5C methylation levels, which further reduces viral RNA stability, replication as well as viral assembly and budding. HCV RNA genomic m5C specific abrogating mutation at C7525 site reduces viral replication, assembly, and budding through decreasing viral RNA stability. Deficiency of NSUN2 also reduces host global messenger RNA (mRNA) m5C modification levels during HCV infection, which upregulates antiviral innate immune response genes expression and further suppresses HCV RNA replication. Supported by both cellular and mouse infection models, our findings reveal that NSUN2-mediated HCV RNA and host mRNA m5C methylations facilitate viral RNA replication. HCV infection promotes host NSUN2 expression to facilitate HCV replication, which implies a positive feedback loop. NSUN2 could be a potential new target for Flavivirus therapeutics.
The triple integration of data, users and policies required for successful climate health solutions
Authors: Sören Becker, Razieh Rezabeigisani
Journal: npj Digital Medicine (2025)

The development of digital tools for climate health is considered an emerging field of action and an economic opportunity. Analysing international best practices, we propose a typology of these technologies and their functions. Climate health technologies share common challenges regarding data integration, the integration of users and policy alignment. Their effectiveness in enhancing public health depends on addressing these challenges through robust data integration, active user engagement, and policy coherence.
Prognostic Value of 18F-FDG PET in Primary Central Nervous System Lymphoma
Authors: Ga-Young Song, Ho Cheol Jang, Mihee Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Jae-Sook Ahn, Je-Jung Lee, Hyeoung-Joon Kim, Jang Bae Moon, Su Woong Yoo, Seong-Young Kwon, Jung-Joon Min, Hee-Seung Bom, Sae-Ryung Kang, Deok-Hwan Yang
Journal: Clinical Nuclear Medicine (2025)

Purpose of the Report The usefulness of brain 18 F-FDG PET/CT in primary central nervous system lymphoma (PCNSL) remains underexplored. This study investigated whether early metabolic responses in interim brain FDG PET/CT serve as a prognostic indicator of PCNSL treatment outcomes. Patients and Methods This prospective study included 53 patients with PCNSL who underwent a high-dose methotrexate–based treatment. Brain FDG PET was performed at diagnosis (baseline PET) and after induction chemotherapy (interim PET), assessing interim PET parameters such as the highest maximum standardized uptake value (hSUV max ), sum of SUV max (sumSUV max ), highest tumor-to-normal ratio (hTNR max ), sum of TNR max (sumTNR max ), highest metabolic tumor volume (MTV) (hMTV), and sum of MTV (sumMTV) across all PET-positive lesions. Results High interim hTNR max (hazards ratio: 9.76, 95% confidence interval: 1.90–50.11, P = 0.01) was an independently significant predictor of poor progression-free survival in multivariate analysis. Patients with low interim hTNR max (≤1.0) had a significantly longer median progression-free survival than those with high interim hTNR max (&gt;1.0) (25.0 vs 3.6 months, P &lt; 0.001). Incorporating interim MRI-based clinical response assessments and hTNR max allowed the classification of partial response subgroups with markedly different prognoses ( P &lt; 0.001). High interim hTNR max (hazards ratio: 2.76, 95% confidence interval: 1.39–5.48, P = 0.004) was an independently significant predictor of poor overall survival in multivariate analysis. Conclusions The hTNR max measurement from interim brain FDG PET scans emerges as an important prognostic marker in PCNSL. These findings underscore the potential of interim FDG PET evaluations to refine response assessments and inform tailored therapeutic strategies.
Scintigraphic Improvement of Primary Intestinal Lymphangiectasia in a Patient Treated With Alpelisib for a PIK3CA-Related Overgrowth Spectrum
Authors: Julien Dubois, Fabien Vauchot
Journal: Clinical Nuclear Medicine (2025)

Abstract A 33-year-old man with primary intestinal lymphangiectasia (Waldmann disease) associated with PIK3CA-related overgrowth spectrum was explored using 99m Tc serum albumin scintigraphy before and during treatment by alpelisib, a specific PIK3CA inhibitor. Before treatment, scintigraphic images evidenced a focal uptake on the right colonic angle 4 hours postinjection (p.i.), diffusing to the transverse and left colon 24 hours p.i., compatible with a diffuse colonic exudation. Significant scintigraphic improvement was observed with a disappearing of the right colonic angle uptake 4 hours p.i. and later images 14 months after alpelisib introduction.
Concerns regarding the study on circulating <scp>GDF</scp>‐15 levels and diastolic dysfunction. Letter regarding the article ‘Circulating growth differentiation factor‐15 levels are associated with early echocardiographic signs of diastolic dysfunction impairment in the <scp>STANISLAS</scp> cohort: A 20‐year follow‐up study’
Authors: Lei Shi
Journal: European Journal of Heart Failure (2025)
Organ perfusion pressure predicts outcomes in cardiogenic shock patients
Authors: Pier Paolo Bocchino, Simone Frea, Alice Sacco, Maurizio Bertaina, Federico Pappalardo, Guido Tavazzi, Nuccia Morici, Filippo Angelini, Laura Garatti, Martina Briani, Carlotta Sorini Dini, Luca Villanova, Guglielmo Gallone, Amelia Ravera, Letizia Bertoldi, Anna Corsini, Giulia Maj, Luciano Potena, Rita Camporotondo, Costanza Natalia Julia Colombo, Andrea Montisci, Fabrizio Oliva, Mario Iannaccone, Nicoletta D'Ettore, Serafina Valente, Matteo Pagnesi, Marco Metra, Marco Marini, Gaetano Maria De Ferrari
Journal: European Journal of Heart Failure (2025)
Motor‐Free Soft Robots for Cancer Detection, Surgery, and In Situ Bioprinting
Authors: Chi Cong Nguyen, James Davies, Aditya Ashok, Trung Thien Hoang, Anahid Ehteda, Tran Bach Dang, Emanuele Nicotra, Hien A. Tran, Bibhu Sharma, Kefan Zhu, Phuoc Thien Phan, Adrienne Ji, Jingjing Wan, Jelena Rnjak‐Kovacina, Orazio Vittorio, Hoang‐Phuong Phan, Nigel Hamilton Lovell, Thanh Nho Do
Journal: Advanced Healthcare Materials (2025)

Abstract Recent advancements in teleoperated surgical robotic systems (TSRSs) for minimally invasive surgery (MIS) have significantly improved diagnostic and surgical outcomes. However, as the complexity of MIS procedures continues to grow, there is an increasing need to enhance surgical tools by integrating advanced functionalities into these instruments for superior medical results. Despite recent advancements, TSRSs face significant challenges, including rigidity, suboptimal actuation methods, large sizes, and complex control mechanisms. This paper presents a portable, motor‐free soft robotic system equipped with soft robotic arms (SRAs) that provides an innovative solution for performing MIS within complex human organs. Unlike conventional approaches, these SRAs leverage a soft fibrous syringe architecture for operation, eliminating the need for complex control systems. This design achieves precise motion control with mean errors &lt;300 µm, effectively minimizing physical tremors. Two SRAs—one with and one without a central lumen—are developed. By integrating microelectrodes into the SRAs, the system demonstrates capabilities to support cancer detection via electrical impedance measurements and to perform radio‐frequency ablation for surgical treatments. Additionally, the system supports biomaterial injections and in situ 3D printing for internal wound healing. This simple, cost‐effective platform represents a promising new direction for developing TSRSs in MIS.
“Self‐Capped” Carbon Dots with Excellent Anti‐Bacteria Effect and an Extremely Low Cytotoxicity Applied for Hand Sanitizer
Authors: Meiyan Wang, Nannan Peng, Weixia Qin, Haimei Zhu, Khurram Abbas, Yan Li, Zijian Li, Jingmin Wang, Hong Bi
Journal: Advanced Healthcare Materials (2025)

Abstract The increasing challenge of antibiotic resistance necessitates the development of novel antibacterial strategies. In this study, a novel kind of self‐capped carbon dots is synthesized from methylene blue (MB) and cetyltrimethylammonium chloride (CTAC), and named as MC‐CDs that are specifically designed for enhanced photodynamic antibacterial activity. Under 660 nm laser irradiation, MC‐CDs demonstrate high inactivation rates of Escherichia coli (96.83%) and Staphylococcus aureus (94.44%) at 14 and 18 µg mL −1 effectively, disrupting bacterial cell membranes. The incorporation of zinc cations (Zn 2+ ) doping further enhances the antibacterial potential of MC‐CDs, enabling substantial efficacy even in the absence of light due to improved electrostatic interactions with bacterial membranes. In comparison to commercial agents such as salicylic acid, p ‐chloro‐ m ‐xylenol, and triclosan, Zn@MC‐CDs exhibit superior antibacterial performance. When formulated into a hand sanitizer, Zn@MC‐CDs maintained over 90% efficacy, displaying excellent stability and extremely low cytotoxicity, highlighting their potential for safe and effective use in personal hygiene products. This study introduces self‐capped carbon dot as a promising antibacterial agent, addressing a critical need for advanced and reliable solutions in infection control.
The Effect of Severe Sepsis and Septic Shock Management Bundle (SEP-1) Compliance and Implementation on Mortality Among Patients With Sepsis
Authors: James S. Ford, Joseph C. Morrison, May Kyaw, Meghan Hewlett, Peggy Tahir, Sonia Jain, Shamim Nemati, Atul Malhotra, Gabriel Wardi
Journal: Annals of Internal Medicine (2025)

The Centers for Medicare & Medicaid Services (CMS) Severe Sepsis and Septic Shock Management Bundle (SEP-1) is now included in the Hospital Value-Based Purchasing (VBP) Program. To assess the evidence supporting SEP-1 compliance or SEP-1 implementation in improving sepsis mortality. PubMed, Web of Science, EMBASE, CINAHL Complete, and Cochrane Library from inception to 26 November 2024. Studies of adults with sepsis that included 3- or 6-hour sepsis bundles defined by SEP-1 specifications. Article screening, full-text review, data extraction, and risk-of-bias assessment were independently performed by 2 authors. Level of evidence was determined using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria and National Quality Forum criteria. A total of 4403 unique references were screened, and 17 studies were included. Twelve studies assessed the relationship between SEP-1 compliance and mortality; 5 showed statistically significant benefit, whereas 7 did not. Among studies showing benefit, 1 did not adjust for confounders, 1 found benefit only among patients with severe sepsis, 1 included only patients with septic shock, and 1 included only Medicare beneficiaries. Five studies assessed the relationship between SEP-1 implementation and sepsis mortality; only 1 showed significant benefit, but it did not adjust for mortality trends before SEP-1 implementation. All 17 studies were observational, and none had low risk of bias. The conclusions are limited by the underlying quality of the available studies, as all were observational. Because there was considerable methodologic heterogeneity among the included studies, a meta-analysis was not performed as the results could have been misleading. This review found no moderate- or high-level evidence to support that compliance with or implementation of SEP-1 was associated with sepsis mortality. CMS should reconsider the addition of SEP-1 to the Hospital VBP Program. None. (PROSPERO: CRD42023482787).
De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome
Authors: Yong-Joon Lee, Xiaofei Gao, Sang-Hyup Lee, Jing Kan, Jun-Jie Zhang, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Byeong-Keuk Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Gregg W. Stone, Shao-Liang Chen, Myeong-Ki Hong
Journal: Annals of Internal Medicine (2025)

The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive. To compare the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT from randomized clinical trials in patients with ACS. PubMed, EMBASE, Scopus, and ClinicalTrials.gov from inception to 12 December 2024. Randomized clinical trials comparing de-escalating DAPT to ticagrelor monotherapy versus ticagrelor-based standard DAPT for 12 months, specifically in patients with ACS undergoing DES implantation. The coprimary end points were an ischemic end point (composite of death, nonprocedural [spontaneous] myocardial infarction, or stroke) and a bleeding end point (Bleeding Academic Research Consortium types 3 or 5 bleeding). Individual patient data were obtained from 3 trials (TICO [Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus-Eluting Stent for Acute Coronary Syndrome], T-PASS [Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome], and ULTIMATE-DAPT [Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes]), including 9130 randomized patients with ACS; 3132 had ST-segment elevation myocardial infarction (STEMI), 3023 had non-STEMI (NSTEMI), and 2975 had unstable angina. The rate of the primary ischemic end point was not different between the ticagrelor monotherapy and standard DAPT groups (1.7% vs. 2.1%; hazard ratio [HR], 0.85 [95% CI, 0.63 to 1.16]). The rate of the primary bleeding end point was lower in the ticagrelor monotherapy group (0.8% vs. 2.5%; HR, 0.30 [CI, 0.21 to 0.45]). These findings were consistent in patients with STEMI, NSTEMI, and unstable angina. Other de-escalation strategies for modulating antiplatelet therapy were not included. In patients with ACS undergoing DES implantation, de-escalating DAPT to ticagrelor monotherapy was associated with a lower risk for major bleeding compared with standard DAPT, without an increase in ischemic events, regardless of the type of ACS. None. (PROSPERO: CRD42024565855).
The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful?
Authors: Miguel A. Hernán, Issa J. Dahabreh, Barbra A. Dickerman, Sonja A. Swanson
Journal: Annals of Internal Medicine (2025)

When randomized trials are not available to answer a causal question about the comparative effectiveness or safety of interventions, causal inferences are drawn using observational data. A helpful 2-step framework for causal inference from observational data is 1) specifying the protocol of the hypothetical randomized pragmatic trial that would answer the causal question of interest (the target trial), and 2) using the observational data to attempt to emulate that trial. The target trial framework can improve the quality of observational analyses by preventing some common biases. In this article, we discuss the utility and scope of applications of the framework. We clarify that target trial emulation resolves problems related to incorrect design but not those related to data limitations. We also describe some settings in which adopting this approach is advantageous to generate effect estimates that can close the gaps that randomized trials have not filled. In these settings, the target trial framework helps reduce the ambiguity of causal questions.
Manual vs AI-Assisted Prescreening for Trial Eligibility Using Large Language Models—A Randomized Clinical Trial
Authors: Ozan Unlu, Matthew Varugheese, Jiyeon Shin, Samantha M. Subramaniam, David Walter Jacques Stein, John J. St Laurent, Charlotte J. Mailly, Marian J. McPartlin, Fei Wang, Michael F. Oates, Christopher P. Cannon, Benjamin M. Scirica, Kavishwar B. Wagholikar, Samuel J. Aronson, Alexander J. Blood
Journal: JAMA (2025)

This randomized clinical trial compares the efficiency of prescreening patients with heart failure using an artificial intelligence (AI) large language model for inclusion in a clinical trial vs manual prescreening.
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
Authors: Che-Hsing Li, Sandhya Sharma, Andras A. Heczey, Mae L. Woods, David H. M. Steffin, Chrystal U. Louis, Bambi J. Grilley, Sachin G. Thakkar, Mengfen Wu, Tao Wang, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop
Journal: Nature Medicine (2025)
Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: a five-year cohort study in intensive care patients
Authors: Stamatis Karakonstantis, Evangelos I Kritsotakis, Renatos-Nikolaos Tziolos, Loukia Vassilopoulou, Maria Loukaki, Despoina Kypraiou, Emmanouil C Petrakis, Alberto Tovil, Sophia Kokkini, Kyriaki Tryfinopoulou, Petros Ioannou, Εumorfia Kondili, Diamantis P Kofteridis
Journal: Clinical Microbiology and Infection (2025)
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
Authors: Saurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, Horatiu Olteanu, Francis Buadi, Pedro Horna, Wilson Gonsalves, Gregory Otteson, Abiola Bukunmi Bolarinwa, Suzanne Hayman, Nadine Abdallah, Moritz Binder, Joselle Cook, Angela Dispenzieri, David Dingli, Morie A. Gertz, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Michelle Rogers, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood Cancer Journal (2025)
Prediction and prevention of post-procedural bleedings in patients with cirrhosis
Authors: Alix Riescher-Tuczkiewicz, Pierre-Emmanuel Rautou
Journal: Clinical and Molecular Hepatology (2025)

Although post-procedural bleedings are infrequent in patients with cirrhosis, they are associated with a significant morbidity and mortality. Therefore, predicting and preventing such bleedings is important. Established predictors of post-procedural bleedings include high-bleeding risk procedure, severe cirrhosis and high body mass index; prognostic value of anemia, acute kidney injury and bacterial infection is more uncertain. While prothrombin time and international normalized ratio do not predict post-procedural bleeding, some evidence suggests that platelet count, whole blood thrombin generation assay and viscoelastic tests may be helpful in this context. Prevention of post-procedural bleeding involves careful management of antithrombotic drugs during the periprocedural period. Patients with cirrhosis present unique challenges due to altered pharmacokinetics and pharmacodynamics of antithrombotic drugs, but there is a lack of dedicated studies specifically focused on this patient population. Guidelines for periprocedural management of antithrombotic drugs developed for patients without liver disease, are thus applied to those with cirrhosis. Some technical aspects may decrease the risk of post-procedural bleeding, namely ultrasound-guidance, opting for transjugular route rather than percutaneous route, and the level of expertise of the operator. The effectiveness of platelet transfusions, or thrombopoietin-receptor agonists remains uncertain. Transfusion of fresh-frozen plasma, of fibrinogen, and administration of tranexamic acid are not recommended for reducing post-procedural bleeding in patients with cirrhosis. In conclusion, prediction of post-procedural requires a global approach taking into account the patients characteristics, the risk of the procedure, and the platelet count. There is little data to support prophylactic correction of hemostasis, and dedicated studies are needed.